Hydrochloride approval & Atorvastatin patent filing
- The Brazilian health agency ANVISA has approved Esketamine Hydrochloride for the first time, going to Supriya Lifescience.
- Atorvastatin, a vital medication used globally to lower cholesterol and prevent cardiovascular disease, may now be produced at a low cost thanks to a novel process created by Supriya Lifescience..
Leading the pharmaceutical sector globally, Supriya Lifescience Ltd., strengthened its position in foreign markets by achieving two noteworthy milestones. In a significant move to expand its product line in Brazil and the rest of Latin America, the business has received permission for esketamine hydrochloride from ANVISA (Agência Nacional de Vigilância Sanitária), Brazil’s health authority. The first company in Brazil to obtain regulatory approval for this extremely specialized medication is Supriya Lifescience.
Esketamine hydrochloride is an essential medication for the treatment of mental illness and is anticipated to have a major effect on the LATAM market. With this approval, the business will be able to offer cutting-edge, superior healthcare solutions in a market where there is an increasing need for innovative, affordable medications.
Additionally, the company filed a groundbreaking patent application for an improved, less expensive atorvastatin synthesis technique. This innovative method lowers production costs while improving medicine efficacy, making medications more accessible to patients. Atorvastatin, a crucial medication for lowering cholesterol and avoiding cardiovascular disease, is used extensively in global healthcare. This accomplishment demonstrates Supriya’s commitment to lowering medicine costs and increasing accessibility.
“Our invention in the synthesis of atorvastatin demonstrates our commitment to transforming pharmaceutical manufacturing while maintaining affordability,” said Dr. Satish Wagh, Executive Chairman and Full-Time Director, Supriya Lifescience Ltd. The CADIFA certification enhances our worldwide reach and enables us to launch innovative treatments like esketamine hydrochloride in key international markets, beginning with Brazil.
Now that Supriya Lifescience has received CADIFA clearance, it is prepared to enter the rapidly expanding LATAM market. The company is positioned as a major participant in the global pharmaceutical scene because to its ongoing focus on innovation, regulatory compliance, and its aim to provide high-quality healthcare globally.
